FDC Limited has informed the Exchange about ANDA approval
FDC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
FDC Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fluconazole Tablets USP in four strengths — 50 mg, 100 mg, 150 mg, and 200 mg. Fluconazole is a widely used antifungal medication, and this approval allows FDC to manufacture and market the generic version in the U.S. market. The filing was made to both BSE and NSE under SEBI Listing Regulations. The approval strengthens FDC's presence in the U.S. generic pharmaceutical space, which is a key export market for Indian pharma companies.
Positive for the stock — U.S. generic approvals typically open up a new revenue stream and reinforce the company's export growth prospects, though actual sales impact will depend on market launch timing and competition.